Hai cercato la traduzione di vitamiin k defitsiit da Estone a Inglese

vitamiin k
vitamin k

vitamiin k (μg)
vitamin k (μg)

vitamiin k antagonistid
vitamin k antagonists

vitamiin k (g) 1 - 4
vitamin k (ìg) 1 - 4

vitamiin k füllokinoon (fütomenadioon)
vitamin k phylloquinone (phytomenadione)

pradaxa-ravilt vitamiin k antagonistidele (vka)
pradaxa treatment to vitamin k antagonists (vka)

lõpetage vitamiin k antagonisti sisaldava ravimi kasutamine.
stop taking the medicine containing a vitamin k antagonist.

Üleminek eliquisi kasutamiselt vitamiin k antagonistile (vka)
switching from eliquis to vka therapy

koostoime varfariiniga ning vitamiin k antagonistidega põhjustavad pikenenud inr- i.
interaction with warfarin and vitamin k antagonists leading to an increased inr

mõlemad ravigrupid said ka ravi vitamiin k antagonistidega, mis tavaliselt algas av
both treatment groups received vitamin k antagonist therapy usually initiated within 72 hours after the first study drug administration and continued for 90 ± 7 m

eliquisi manustamist koos vitamiin k antagonistiga tuleb jätkata kuni inr on ≥ 2.
coadministration of eliquis and vka therapy should be continued until the inr is ≥ 2.

Üleminek eliquisiga ravilt vitamiin k antagonisti (nt varfariini) sisaldava antikoagulandi kasutamisele
changing from eliquis to anticoagulant treatment containing vitamin k antagonist (e.g., warfarin).

proteiin c on vitamiin k-st sõltuv antikoagulatiivsete omadustega glükoproteiin, mida sünteesitakse maksas.
protein c is a vitamin k-dependent anticoagulant glycoprotein which is synthesised in the liver.

kui on vaja, tuleb samaaegselt rakendada ravi vitamiin k antagonistidega, vastavalt informatsioonile lõigus 4. 5.
when required, concomitant therapy with vitamin k antagonist should be administered in accordance with the information of section 4.5.

kui järelravi nõuab vitamiin k antagonistide kasutamist, tuleb ravi fondapariinuksiga jätkata kuni on saavutatud inr vajalik väärtus.
if follow up treatment with a vitamin k antagonist is required, treatment with fondaparinux should be continued until the target inr value has been reached.

mõlemad ravigrupid said ka ravi vitamiin k antagonistidega, mis tavaliselt algas 72 tunni jooksul alates esimesest uuringuravimi manustamisest ja av
both treatment groups received vitamin k antagonist therapy usually initiated within 72 hours after the first study drug administration and continued for 90 ± 7 ct

kaasnev ravi kumariiniderivaatidega (vitamiin k antagonistidega) ja trombotsüütide funktsiooni mõjutavate ravimitega võib samuti tõsta verejooksu ohtu.
concomitant treatment with coumarin derivatives (vitamin k antagonists) and drugs that affect platelet function may also increase the risk of bleeding.

thelin suurendab vitamiin k antagonistide, nagu näiteks varfariini, atsenokumarooli ja fenprokumooni plasmakontsentratsioone (vt lõik 4.5).
thelin increases the plasma levels of vitamin k antagonists such as warfarin, acenocoumarol and fenprocoumon (see section 4.5).

kui patsient viiakse eliquisi kasutamiselt üle ravile vitamiin k antagonistiga, tuleb eliquisi manustamist jätkata vähemalt 2 päeva pärast vitamiin k antagonistiga ravi alustamist.
when converting patients from eliquis to vka therapy, administration of eliquis should be continued for at least 2 days after beginning vka therapy.

farmakoterapeutiline rühm: verejooksu tõkestavad ained, vitamiin k ja teised hemostaatilised ained, x hüübimisfaktor, atc-kood: b02bd13.
pharmacotherapeutic group: anti-haemorrhagics, vitamin k and other haemostatics, coagulation factor x, atc code: b02bd13.